Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1].
Molecular Weight:
(145.48 kDa)
Purity:
99.59
CAS Number:
[219649-07-7]
Target:
Transmembrane Glycoprotein
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
